Literature DB >> 25603449

Use of antipsychotic medications in pediatric and young adult populations: future research needs.

Robert B Christian1, Bradley N Gaynes, Lissette M Saavedra, Brian Sheitman, Roberta Wines, Daniel E Jonas, Meera Viswanathan, Alan R Ellis, Carol Woodell, Timothy S Carey.   

Abstract

The use of antipsychotics, particularly second generation antipsychotics, among children and adolescents has increased markedly during the past 20 years. Existing evidence gaps make this practice controversial and hinder treatment decision-making. This article describes and prioritizes future research needs regarding antipsychotic treatment in youth, focusing on within-class and between-class drug comparisons with regard to key population subgroups, efficacy and effectiveness outcomes, and adverse event outcomes. Using as a foundation a recent systematic review of antipsychotic treatment among youth, which was completed by a different Evidence-based Practice Center, we worked with a diverse group of 12 stakeholders representing researchers, funders, health care providers, patients, and families to identify and prioritize research needs. From an initial list of 16 evidence gaps, we enumerated 6 high-priority research needs: 1) long-term comparative effectiveness across all psychiatric disorders; 2) comparative long-term risks of adverse outcomes; 3) short-term risks of adverse events; 4) differentials of efficacy, effectiveness, and safety for population subgroups; 5) comparative effectiveness among those with attention-deficit/hyperactivity disorder and disruptive behavior disorders and common comorbidities; 6) comparative effectiveness among those with bipolar disorder and common comorbidities. In this article, we describe these future research needs in detail and discuss study designs that could be used to address them.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25603449     DOI: 10.1097/01.pra.0000460619.10429.4c

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  4 in total

1.  Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine.

Authors:  Mari S Golub; Casey E Hogrefe; Alicia M Bulleri
Journal:  Neuropharmacology       Date:  2016-02-22       Impact factor: 5.250

2.  Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents.

Authors:  Minji Sohn; Jeffery Talbert; Karen Blumenschein; Daniela Claudia Moga
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-03-23       Impact factor: 2.890

3.  Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education.

Authors:  Kristin Bussell; Gloria Reeves; Erin Hager; Shijun Zhu; Christoph U Correll; Mark A Riddle; Linmarie Sikich
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06       Impact factor: 3.031

Review 4.  Fluoxetine Administration in Juvenile Monkeys: Implications for Pharmacotherapy in Children.

Authors:  Mari S Golub; Casey E Hogrefe; Richard J Sherwood; Christoph W Turck
Journal:  Front Pediatr       Date:  2018-02-08       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.